Orca Trial

 Orca-T Trial Info.

I qualified for the Orca-T Trial. I have quickly pasted an AI Overview of the trials benefits. I will elaborate more when I have more information

"Orca-T" is an investigational, precision-engineered T-cell immunotherapy designed to improve outcomes for blood cancer patients undergoing stem cell transplants. In clinical trials, it has proven highly effective at preventing severe graft-versus-host disease (GVHD) without increasing the risk of cancer relapse.

What is Orca-T?

Developed by Orca Bio, Orca-T is a cell therapy that replaces a patient's diseased blood and immune system with a healthy one. Unlike standard transplants, it is highly purified to include a precise balance of stem cells, regulatory T-cells, and conventional T-cells. This engineering helps the donor immune system fight the cancer while preventing the body from attacking healthy tissue (GVHD)

Key Trial Findings

• The Precision-T Study (NCT04013685): A pivotal Phase 3 randomized trial enrolling 187 adult patients with acute leukemias and myelodysplastic syndrome (MDS).
• Reduced GVHD: Patients treated with Orca-T experienced a statistically significant reduction in moderate-to-severe chronic GVHD (78% free from GVHD) compared to those receiving conventional transplants (38%).
• Relapse-Free Survival: The trial successfully met its primary goal without compromising relapse rates; one-year relapse-free survival was highly comparable between the Orca-T and standard arms (76% vs. 74%).
• Reduced Immunosuppression: Orca-T patients required significantly less immunosuppressive medication post-transplant.

Current Status & Active Trials

• FDA Status: The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for Orca-T and granted it Priority Review for hematological malignancies.
• SERENE-T Trial (NCT07216443): An active Phase 2 multicenter study specifically evaluating Orca-T in adults with acute myeloid leukemia (AML) and MDS who are receiving reduced-intensity or non-myeloablative conditioning.